150
Participants
Start Date
December 16, 2016
Primary Completion Date
March 12, 2017
Study Completion Date
March 12, 2017
Blood draw
Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49\_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
GSK Investigational Site, Mengshan
Lead Sponsor
GlaxoSmithKline
INDUSTRY